RemeGen Management

Management criteria checks 3/4

RemeGen's CEO is Jianmin Fang, appointed in Oct 2008, has a tenure of 15.92 years. total yearly compensation is CN¥14.66M, comprised of 37% salary and 63% bonuses, including company stock and options. directly owns 11.44% of the company’s shares, worth HK$1.25B. The average tenure of the management team and the board of directors is 2.7 years and 4.3 years respectively.

Key information

Jianmin Fang

Chief executive officer

CN¥14.7m

Total compensation

CEO salary percentage	37.0%
CEO tenure	15.9yrs
CEO ownership	11.4%
Management average tenure	2.7yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jianmin Fang's remuneration changed compared to RemeGen's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-CN¥2b
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥15m	CN¥5m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥27m	CN¥5m	-CN¥999m
Sep 30 2022	n/a	n/a	CN¥276m
Jun 30 2022	n/a	n/a	CN¥231m
Mar 31 2022	n/a	n/a	CN¥174m
Dec 31 2021	CN¥8m	CN¥4m	CN¥276m

Compensation vs Market: Jianmin's total compensation ($USD2.08M) is above average for companies of similar size in the Hong Kong market ($USD565.65K).

Compensation vs Earnings: Jianmin's compensation has been consistent with company performance over the past year.

CEO

Jianmin Fang (61 yo)

15.9yrs

Tenure

CN¥14,658,000

Compensation

Dr. Jianmin Fang is Co-Founder at RemeGen Co. Ltd. He has been Director, Chief Executive Officer and GM of RemeGen Co. Ltd. and served as its Chief Scientific Officer since October 16, 2008 to 2023 and red...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Weidong Wang	Co-Founder & Executive Chairman	10.9yrs	CN¥15.15m	no data
Jianmin Fang	Co-Founder	15.9yrs	CN¥14.66m	11.44% CN¥ 1.3b
Shaojing Tong	CFO & Joint Company Secretary	less than a year	CN¥1.25m	no data
Ruyi He	Chief Medical Officer	no data	CN¥24.01m	0.00090% CN¥ 98.6k
Jian Lin	Executive Director	no data	CN¥1.13m	no data
Kaisheng Huang	Chief Operating Officer	no data	no data	no data
Marie Zhu	Chief Technical Officer	no data	no data	no data
Zhulun Wang	Chief Scientific Officer	no data	no data	no data
Daniel Ross	Chief Business Officer	less than a year	no data	no data
Xiaoming Yang	Chief Manufacturing Officer	no data	no data	no data
Qingkai Wen	Board Secretary	4.3yrs	no data	no data

2.7yrs

Average Tenure

61yo

Average Age

Experienced Management: 9995's management team is considered experienced (2.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Weidong Wang	Co-Founder & Executive Chairman	10.9yrs	CN¥15.15m	no data
Jianmin Fang	Co-Founder	15.9yrs	CN¥14.66m	11.44% CN¥ 1.3b
Ruyi He	Chief Medical Officer	4.3yrs	CN¥24.01m	0.00090% CN¥ 98.6k
Jian Lin	Executive Director	16.2yrs	CN¥1.13m	no data
Lorne Alan Babiuk	Member of Scientific Advisory Board	no data	CN¥125.00k	no data
Gang Pei	Member of Scientific Advisory Board	no data	no data	no data
Liqiang Wang	Non-Executive Director	4.3yrs	no data	4.69% CN¥ 514.0m
Xiaodi Su	Non-Executive Director	4.3yrs	no data	no data
Xianjing Hao	Independent Non-Executive Director	4.3yrs	CN¥300.00k	no data
Guangke Ren	Chairman of the Supervisory Board	4.3yrs	no data	no data
Lan Ma	Independent Non-Executive Director	3.3yrs	CN¥300.00k	no data
Yunjin Chen	Independent Non-Executive Director	2.3yrs	CN¥300.00k	no data

4.3yrs

Average Tenure

61yo

Average Age

Experienced Board: 9995's board of directors are considered experienced (4.3 years average tenure).

RemeGen Management

Management criteria checks 3/4

Key information

Recent management updates

RemeGen Co., Ltd., Annual General Meeting, Jun 28, 2024

Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary

Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer

RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary

Less than half of directors are independent

RemeGen Co., Ltd., Annual General Meeting, Jun 29, 2022

Recent updates

New major risk - Market cap size

New major risk - Financial position

Second quarter 2024 earnings released: CN¥0.80 loss per share (vs CN¥0.70 loss in 2Q 2023)

RemeGen Co., Ltd. Announces First Patient Enrollment in the U.S for Its Global Multi-Center Phase III Clinical Trial for the Treatment of Generalized Myasthenia Gravis

RemeGen Co., Ltd. Announces Full Approval of Telitacicept for the Treatment of Patients with Rheumatoid Arthritis by NMPA

New minor risk - Profitability

RemeGen Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

RemeGen Co., Ltd. Announces Phase III Clinical Study of Disitamab Vedotin for Injection for the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis Met Primary Study Endpoint

RemeGen Co., Ltd., Annual General Meeting, Jun 28, 2024

Full year 2023 earnings released: CN¥2.80 loss per share (vs CN¥1.88 loss in FY 2022)

New minor risk - Profitability

RemeGen Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer At ESGO 2024

Full year 2023 earnings released: CN¥2.86 loss per share (vs CN¥1.88 loss in FY 2022)

RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023

New minor risk - Share price stability

RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients

RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA

RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology

Third quarter 2023 earnings released

Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary

Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer

RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary

Second quarter 2023 earnings released: CN¥0.70 loss per share (vs CN¥0.38 loss in 2Q 2022)

RemeGen Co., Ltd. Announces Results of Phase III Study on Telitacicept for Treatment of Rheumatoid Arthritis in China

New minor risk - Share price stability

RemeGen Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Now 20% undervalued after recent price drop

Remegen Co., Ltd. Receives Ethics Approval for the Phase I Clinical Trial in Australia

Now 21% undervalued after recent price drop

Full year 2022 earnings released: CN¥1.81 loss per share (vs CN¥0.57 profit in FY 2021)

RemeGen Co., Ltd. Announces FDA Approves Ind Application for Telitacicept for Treatment of gMG and Grants It Fast Track Designation

National Medical Products Administration Approves IND Application for RemeGen’s Disitamab Vedotin for Injection, Given Intravenously, in Combination with Gemcitabine Hydrochloride for Injection, Given Intravesically, for Treatment of NMIBC

RemeGen Co., Ltd.'s RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA

Less than half of directors are independent

RemeGen Co., Ltd. Announces Telitacicept Propose to Grant Telitacicept Breakthrough Therapy Designation for the Treatment of Generalised Myasthenia Gravis

RemeGen Co., Ltd. Announces Results of Phase Ii Clinical Study of Telitacicept for Treatment of Myasthenia Gravis (MG) in China

Third quarter 2022 earnings released: CN¥0.37 loss per share (vs CN¥0.74 profit in 3Q 2021)

RemeGen Co., Ltd. to Report Nine Months, 2022 Results on Oct 27, 2022

Remegen Co., Ltd. Receives Orphan Drug Designation from FDA for Treatment of Myasthenia Gravis

Investor sentiment deteriorated over the past week

RemeGen Co., Ltd. Announces Preliminary Result of Telitacicept in the Phase III Comfirmatory Study to Treat Systemic Lupus Erythematosus in China

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released

RemeGen Co., Ltd. to Report Q2, 2022 Results on Aug 26, 2022

RemeGen Co., Ltd., Annual General Meeting, Jun 29, 2022

RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director

Less than half of directors are independent

RemeGen Co., Ltd. Announces Executive Changes

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Forecast breakeven date moved forward to 2022

Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

RemeGen Co., Ltd. Completes the Phase II Clinical Study for Telitacicept to Treat Patients with Primary Sjögren's Syndrome (pSS) in China and Obtained the Relevant Data Readout

RemeGen Co., Ltd. Announces National Medical Products Administration (Nmpa) Grants Conditional Marketing Approval for Disitamab Vedotin for the Treatment of HER2 Expressing Locally Advanced or Metastatic Urothelial Carcinoma

Forecast breakeven date pushed back to 2023

Forecast breakeven date moved forward to 2021

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment

Forecast to breakeven in 2023

No longer forecast to breakeven

Remegen Co., Ltd. Announces That the National Medical Products Administration (Nmpa) Has Accepted the New Drug Application

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure